Deferasirox in a refractory anemia after other treatment options: case report and literature review

Deferasirox, represents an effective iron chelator drug in lower risk myelodysplastic syndromes. Reduction in oxidative stress is responsible of the hematologic improvement but further explanation may impact on its benefit. Biological and clinical studies are necessary to better define mechanisms of...

Descripción completa

Detalles Bibliográficos
Autor principal: Manduzio, Palma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498843/
https://www.ncbi.nlm.nih.gov/pubmed/26185629
http://dx.doi.org/10.1002/ccr3.262
_version_ 1782380690930663424
author Manduzio, Palma
author_facet Manduzio, Palma
author_sort Manduzio, Palma
collection PubMed
description Deferasirox, represents an effective iron chelator drug in lower risk myelodysplastic syndromes. Reduction in oxidative stress is responsible of the hematologic improvement but further explanation may impact on its benefit. Biological and clinical studies are necessary to better define mechanisms of action, assess toxicities, and predicting factors of response.
format Online
Article
Text
id pubmed-4498843
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-44988432015-07-16 Deferasirox in a refractory anemia after other treatment options: case report and literature review Manduzio, Palma Clin Case Rep Case Reports Deferasirox, represents an effective iron chelator drug in lower risk myelodysplastic syndromes. Reduction in oxidative stress is responsible of the hematologic improvement but further explanation may impact on its benefit. Biological and clinical studies are necessary to better define mechanisms of action, assess toxicities, and predicting factors of response. John Wiley & Sons, Ltd 2015-06 2015-03-29 /pmc/articles/PMC4498843/ /pubmed/26185629 http://dx.doi.org/10.1002/ccr3.262 Text en © 2015 The Author. Clinical Case Reports published by John Wiley & Sons Ltd. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Reports
Manduzio, Palma
Deferasirox in a refractory anemia after other treatment options: case report and literature review
title Deferasirox in a refractory anemia after other treatment options: case report and literature review
title_full Deferasirox in a refractory anemia after other treatment options: case report and literature review
title_fullStr Deferasirox in a refractory anemia after other treatment options: case report and literature review
title_full_unstemmed Deferasirox in a refractory anemia after other treatment options: case report and literature review
title_short Deferasirox in a refractory anemia after other treatment options: case report and literature review
title_sort deferasirox in a refractory anemia after other treatment options: case report and literature review
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498843/
https://www.ncbi.nlm.nih.gov/pubmed/26185629
http://dx.doi.org/10.1002/ccr3.262
work_keys_str_mv AT manduziopalma deferasiroxinarefractoryanemiaafterothertreatmentoptionscasereportandliteraturereview

Ejemplares similares